A chronic, low-dose regimen of the antiprogestin ZK 137 316 prevents pregnancy in rhesus monkeys

Mary Zelinski, K. Chwalisz, S. A. Iliff, C. L. Niemeyer, G. G. Eaton, Donald (Lynn) Loriaux, Ov Slayden, R. M. Brenner, Richard Stouffer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Continual administration of low doses of the antiprogestin ZK 137 316 was previously reported to permit ovarian/menstrual cyclicity, but disrupt endometrial growth in macaques. The contraceptive efficacy of this regimen was tested in female rhesus monkeys (10 per group) treated daily with vehicle (controls), 0.01 or 0.03 mg ZK 137 316 per kg body weight for 30 days before and during continual co-habitation with males of proven fertility. Treatment continued until confirmation of pregnancy or for 5 months after pair-housing with males. Mating and vaginal sperm were evident in all females. A cumulative pregnancy rate of 90% (9/10) was observed in the controls. Of the 10 animals receiving 0.01 mg/kg, four conceived during the first 2 months of pairing (P = 0.06) with no further conceptions. No pregnancies were observed in the 0.03 mg/kg group (P <0.01). Timely, overt menses occurred at a higher frequency in the 0.01 mg/kg group than the 0.03 mg/kg group. However, corpora lutea were present in ovaries from both groups during the last treatment cycle, indicating that ovarian cycles occurred. Thus, chronic administration of low-dose ZK 137 316 that permits continued ovarian cyclicity and a high incidence of timely menses, prevents pregnancy in non-human primates. This regimen may provide a novel method of contraception for women.

Original languageEnglish (US)
Pages (from-to)2132-2138
Number of pages7
JournalHuman Reproduction
Volume13
Issue number8
DOIs
StatePublished - 1998

Fingerprint

Macaca mulatta
Menstruation
Periodicity
Pregnancy
Corpus Luteum
Macaca
Pregnancy Rate
Licensure
Menstrual Cycle
Contraceptive Agents
Contraception
Primates
Fertility
Spermatozoa
Ovary
Body Weight
Incidence
Therapeutics
Growth

Keywords

  • Antiprogestin
  • Contraception
  • Menstrual cycle
  • Pregnancy
  • ZK 137 316

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

A chronic, low-dose regimen of the antiprogestin ZK 137 316 prevents pregnancy in rhesus monkeys. / Zelinski, Mary; Chwalisz, K.; Iliff, S. A.; Niemeyer, C. L.; Eaton, G. G.; Loriaux, Donald (Lynn); Slayden, Ov; Brenner, R. M.; Stouffer, Richard.

In: Human Reproduction, Vol. 13, No. 8, 1998, p. 2132-2138.

Research output: Contribution to journalArticle

Zelinski, Mary ; Chwalisz, K. ; Iliff, S. A. ; Niemeyer, C. L. ; Eaton, G. G. ; Loriaux, Donald (Lynn) ; Slayden, Ov ; Brenner, R. M. ; Stouffer, Richard. / A chronic, low-dose regimen of the antiprogestin ZK 137 316 prevents pregnancy in rhesus monkeys. In: Human Reproduction. 1998 ; Vol. 13, No. 8. pp. 2132-2138.
@article{9ba455f097b9472ca491ad6ba415bb9a,
title = "A chronic, low-dose regimen of the antiprogestin ZK 137 316 prevents pregnancy in rhesus monkeys",
abstract = "Continual administration of low doses of the antiprogestin ZK 137 316 was previously reported to permit ovarian/menstrual cyclicity, but disrupt endometrial growth in macaques. The contraceptive efficacy of this regimen was tested in female rhesus monkeys (10 per group) treated daily with vehicle (controls), 0.01 or 0.03 mg ZK 137 316 per kg body weight for 30 days before and during continual co-habitation with males of proven fertility. Treatment continued until confirmation of pregnancy or for 5 months after pair-housing with males. Mating and vaginal sperm were evident in all females. A cumulative pregnancy rate of 90{\%} (9/10) was observed in the controls. Of the 10 animals receiving 0.01 mg/kg, four conceived during the first 2 months of pairing (P = 0.06) with no further conceptions. No pregnancies were observed in the 0.03 mg/kg group (P <0.01). Timely, overt menses occurred at a higher frequency in the 0.01 mg/kg group than the 0.03 mg/kg group. However, corpora lutea were present in ovaries from both groups during the last treatment cycle, indicating that ovarian cycles occurred. Thus, chronic administration of low-dose ZK 137 316 that permits continued ovarian cyclicity and a high incidence of timely menses, prevents pregnancy in non-human primates. This regimen may provide a novel method of contraception for women.",
keywords = "Antiprogestin, Contraception, Menstrual cycle, Pregnancy, ZK 137 316",
author = "Mary Zelinski and K. Chwalisz and Iliff, {S. A.} and Niemeyer, {C. L.} and Eaton, {G. G.} and Loriaux, {Donald (Lynn)} and Ov Slayden and Brenner, {R. M.} and Richard Stouffer",
year = "1998",
doi = "10.1093/humrep/13.8.2132",
language = "English (US)",
volume = "13",
pages = "2132--2138",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - A chronic, low-dose regimen of the antiprogestin ZK 137 316 prevents pregnancy in rhesus monkeys

AU - Zelinski, Mary

AU - Chwalisz, K.

AU - Iliff, S. A.

AU - Niemeyer, C. L.

AU - Eaton, G. G.

AU - Loriaux, Donald (Lynn)

AU - Slayden, Ov

AU - Brenner, R. M.

AU - Stouffer, Richard

PY - 1998

Y1 - 1998

N2 - Continual administration of low doses of the antiprogestin ZK 137 316 was previously reported to permit ovarian/menstrual cyclicity, but disrupt endometrial growth in macaques. The contraceptive efficacy of this regimen was tested in female rhesus monkeys (10 per group) treated daily with vehicle (controls), 0.01 or 0.03 mg ZK 137 316 per kg body weight for 30 days before and during continual co-habitation with males of proven fertility. Treatment continued until confirmation of pregnancy or for 5 months after pair-housing with males. Mating and vaginal sperm were evident in all females. A cumulative pregnancy rate of 90% (9/10) was observed in the controls. Of the 10 animals receiving 0.01 mg/kg, four conceived during the first 2 months of pairing (P = 0.06) with no further conceptions. No pregnancies were observed in the 0.03 mg/kg group (P <0.01). Timely, overt menses occurred at a higher frequency in the 0.01 mg/kg group than the 0.03 mg/kg group. However, corpora lutea were present in ovaries from both groups during the last treatment cycle, indicating that ovarian cycles occurred. Thus, chronic administration of low-dose ZK 137 316 that permits continued ovarian cyclicity and a high incidence of timely menses, prevents pregnancy in non-human primates. This regimen may provide a novel method of contraception for women.

AB - Continual administration of low doses of the antiprogestin ZK 137 316 was previously reported to permit ovarian/menstrual cyclicity, but disrupt endometrial growth in macaques. The contraceptive efficacy of this regimen was tested in female rhesus monkeys (10 per group) treated daily with vehicle (controls), 0.01 or 0.03 mg ZK 137 316 per kg body weight for 30 days before and during continual co-habitation with males of proven fertility. Treatment continued until confirmation of pregnancy or for 5 months after pair-housing with males. Mating and vaginal sperm were evident in all females. A cumulative pregnancy rate of 90% (9/10) was observed in the controls. Of the 10 animals receiving 0.01 mg/kg, four conceived during the first 2 months of pairing (P = 0.06) with no further conceptions. No pregnancies were observed in the 0.03 mg/kg group (P <0.01). Timely, overt menses occurred at a higher frequency in the 0.01 mg/kg group than the 0.03 mg/kg group. However, corpora lutea were present in ovaries from both groups during the last treatment cycle, indicating that ovarian cycles occurred. Thus, chronic administration of low-dose ZK 137 316 that permits continued ovarian cyclicity and a high incidence of timely menses, prevents pregnancy in non-human primates. This regimen may provide a novel method of contraception for women.

KW - Antiprogestin

KW - Contraception

KW - Menstrual cycle

KW - Pregnancy

KW - ZK 137 316

UR - http://www.scopus.com/inward/record.url?scp=0031670354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031670354&partnerID=8YFLogxK

U2 - 10.1093/humrep/13.8.2132

DO - 10.1093/humrep/13.8.2132

M3 - Article

C2 - 9756284

AN - SCOPUS:0031670354

VL - 13

SP - 2132

EP - 2138

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 8

ER -